Barriers to the implementation of epilepsy genetic testing and counseling guidelines

癫痫基因检测和咨询指南实施的障碍

阅读:2

Abstract

OBJECTIVE: In 2022, the National Society of Genetic Counselors (NSGC) published a practice guideline for genetic testing and counseling for unexplained epilepsy. It is endorsed by the American Epilepsy Society and recommends genetic testing for all patients with unexplained epilepsy (prioritizing exome/genome sequencing [ES/GS] or multi-gene panel [MGP] as first-tier testing) and providing professional pre-/post-test counseling. This study investigates the alignment of neurologists' practice with this guideline and identifies barriers to implementation. METHODS: Neurologists who treat epilepsy in the United States completed a survey about guideline awareness, current practices, and barriers to genetic testing/counseling. Recruitment occurred through newsletters/listservs of professional organizations and public contact information. A total of, 91 participants accessed the survey, and 84 completed enough for inclusion in data analysis. RESULTS: Approximately half (43.9%, 36/82) of participants offer genetic testing to most/all their patients with unexplained epilepsy, while the other half (46.3%, 38/82) offer genetic testing only to patients with epilepsy for whom they suspect a genetic etiology. Neurologists caring for adult patients were significantly more likely than those caring for pediatric patients to fall into the latter category (χ(2)[1, N = 69] = 22.66, p < 0.001). When ordering genetic testing, 75.5% (n = 40/53) of participants choose MGP most often, while 20.8% (n = 11/53) choose ES/GS and 3.8% (n = 2/53) choose microarray. Barriers to genetic testing and pre-/post-test counseling included insurance coverage, test coordination, limited expertise, and access to a genetic counselor (GC). Barriers were more significant for adult providers. Over half of participants (56.1%, n = 46/82) were aware of the NSGC guideline, but almost all (91.3%, n = 36/82) thought it was not broadly publicized. SIGNIFICANCE: Increased insurance coverage, access to GCs, and awareness of guidelines are needed to improve access to genetic testing and counseling for unexplained epilepsies, particularly for the adult population. PLAIN LANGUAGE SUMMARY: In 2022, the National Society of Genetic Counselors published a practice guideline recommending genetic testing and counseling for all patients with unexplained epilepsy, using exome/genome sequencing or a multi-gene panel as the first-tier test. This survey study examined neurologists' current practices compared to the guideline and identified barriers. A total of, 44% of participants offer genetic testing to most/all their patients, while 46% test only when they suspect a genetic cause. Adult neurologists rate most barriers higher than pediatric neurologists. Better insurance coverage and increased access to genetic counselors are key to improving access to epilepsy genetic testing and counseling.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。